Search Results - rengyun+liu

1 Results

Sort By:

A Molecular Mechanism for the Activation of Mutant TERT by the BRAF V600E/MAP Kinase Pathway

Unmet NeedThe oncogenic duet of BRAF V600E and TERT promoter mutations occurs in approximately 7-8% of papillary thyroid cancer (PTC) cases and 20-50% of melanoma cases. These percentages also correspond to the proportion of cases with the poorest clinical and pathological outcomes. When mutations in either of these oncogenes alone are present, only...

Published: 3/14/2025 | Inventor(s): Michael Xing, Rengyun Liu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Clinical and Disease Specializations > Oncology > Melanoma